Skip to main content Skip to footer

New Science

Outcomes in New Science

What is New Science?

Scientific novelty

Enables better understand of future areas of growth in disease and overall therapeutic areas, and better manage portfolio risk.

Unmet need

Measuring treatments that qualify as achieving current unmet need ensures development of medicines for patient impact.

Technology convergence

Measuring medicines that coexist with technology in the near-term and future ensures a better understanding of science’s growing dependence on tech.

Built for Change a podcast from Accenture

New Science-A new economic reality for growth

A conversation with Scott Howell, CSO at Novartis

The new economics of life sciences

Shaping the future with science

A new economic reality for growth

As New Science grows in prominence, a new economic environment is demanding change for biopharma’s.

"The investment in scientific innovation is born by all stakeholders and felt most deeply by patients. Now the goal must be maximizing return on that investment for patients, too. There are better, faster ways to deliver innovation—2020 proved that."

— STUART HENDERSON, Global Lead – Accenture Life Sciences

Case studies

A game-changing new supply chain

With the pandemic, a game-changing new supply chain network was needed for lightspeed delivery and safe...

Speeding an innovative cell therapy to market

A biopharmaceutical company collaborates with Accenture to navigate a complex FDA submission for an innovative cell therapy.

Flawless execution from SAP ECC to S/4HANA

Bristol Myers Squibb upgrades global SAP to S/4HANA in the AWS cloud flawlessly and without business disruption.


Our leaders

Petra Jantzer, Ph.D.

Senior Managing Director – Global Life Sciences Lead

Aman Bajaaj

Managing Director – Asia Pacific Life Sciences Lead

Brad Michel

Managing Director – Life Sciences Lead, North America